Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Six die after Chinese antibody injections
Just as the heparin hoopla was starting to settle down, now China is reporting that six patients in Jiangxi province have died after injections of immunoglobulins. All the injections came from a single batch made by Jiangxi Yabo Bio-Pharmaceutical, which has been ordered to stop producing the drug. China's State Food and Drug Administration has launched an investigation. Penalties for pharma-tampering are severe in China; last month, five officials of a company that sold a tainted antibiotic were sentenced to seven years in prison.
- read the AFP story
- check out the Associated Press article
Related Articles:
U.S., China trade blame on heparin
China launches drug recall system
China to overhaul drug safety regulations
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


